The primary role of Optive UD is to provide supportive symptomatic relief and contributes to improved comfort for individuals experiencing dry eye symptoms. The product is used to help manage symptoms related to eye dryness.

It is relevant for conditions presenting with Dry Eye Disease (DED) and related chronic manifestations, where it helps address symptom clusters that may become intense or disruptive, such as burning, grittiness, soreness, and the feeling of a foreign body in the eye.

The product is applied in scenarios where short-term symptomatic assistance is needed, often associated with prolonged screen time, exposure to air conditioning, or arid climates. For patients with pre-existing ocular sensitivity and those requiring frequent application, the preservative-free unit dose format is applied when appropriate for the patient's needs.

“The drops are commonly used to support patients during difficult episodes by easing symptoms related to physical discomfort and contributing to improved day-to-day comfort.”

Quick Fact: Support for Abrasive Sensations

The formulation assists with maintaining functional stability, which may help make frequent and challenging sensations like scratchiness and grittiness easier to tolerate.

Regulatory References

1. FDA DailyMed overview for ophthalmic lubricants

The eligibility profile for Optive UD is strictly defined by official regulatory documentation, reflecting its action as a topically applied, non-systemic ophthalmic product.

Contraindicated Populations

The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to the active ingredients—Carmellose Sodium and Glycerol—or any other excipient in the formulation. This local intolerance is the sole absolute non-eligibility factor cited in regulatory labeling.

Established and Restricted Eligibility

Use is established and permitted for the general adult and older adult (geriatric) population. Furthermore, due to the regulatory classification confirming negligible systemic exposure, use is permitted during pregnancy and breastfeeding. This negligible systemic effect also means the labeling contains no restrictions based on systemic health conditions such as renal or hepatic impairment.

Eligibility is conditional for the pediatric population (children and adolescents). Regulatory authorities state that the safety and effectiveness for this age group have not been established by formal clinical trial data. The unit dose formulation is officially listed as compatible for use with all types of contact lenses.

The official regulatory interaction profile for Optive UD is structured by its classification as a topical ophthalmic lubricant, meaning it is applied externally and achieves no systemic exposure. Consequently, no systemic pharmacokinetic drug–drug interactions are documented in regulatory prescribing information. Interactions involving metabolic enzymes, such as Cytochrome P450, or drug transporters are considered not applicable, as the product does not reach the necessary drug concentrations in the bloodstream to alter these pathways. This also extends to non-medicinal substances; no interactions are documented between the product and food, alcohol, or herbal supplements.

The single documented interaction pattern is a local pharmacodynamic interaction with other topical ophthalmic medicinal products. This interaction is physical in nature, arising from the potential for the lubricant solution to cause the premature dilution or washout of a co-administered eye drop if the products are used simultaneously or too closely in sequence.

To mitigate the risk of this local physical interference, official government labeling mandates a timing-based interaction rule. Optive UD must be administered at least five minutes after the application of any other topical ocular treatment. This required administration separation is the primary interaction-related restriction defined in regulatory documents. No combinations with any medicinal product or substance are formally classified as contraindicated.

How Optive UD Works

Optive UD employs a dual-action physical mechanism to influence the eye's surface structure, acting on both the tear film's viscosity and the cells' osmotic balance. This approach targets two core mechanistic domains.

Viscosity Modulation and Physical Coating

This domain is driven by Carmellose Sodium, a high-molecular-weight polymer that increases the solution's viscosity and provides a physical barrier over the ocular surface epithelial cells. This action modifies the rate of tear fluid evaporation and facilitates a low-coefficient-of-friction interface during dynamic surface movement, thereby contributing to the mechanical integrity of the eye's outer layer.

Osmotic Correction and Cellular Volume Modulation

This domain is governed by Glycerin, an osmotic agent that targets the tonicity of the tear film. Glycerin establishes a favorable osmotic gradient, which induces the translocation of water into the surface cells to modulate cell volume and tonicity, thereby countering the underlying hyperosmolarity. The resulting physiological effect is cellular volume modulation and the maintenance of surface layer integrity.

Administration Instructions for Optive UD

Optive UD is an ophthalmic product packaged in preservative-free, unit-dose vials. The instructions for its use detail specific dosing, administration, and handling procedures required to maintain product sterility and ensure correct application.

Administration Scope	Instructions
Route	Ophthalmic (instillation into the affected eye(s)).
Dosing	Place 1 or 2 drops in the affected eye(s).
Frequency	Use as needed.
Co-administration	Allow a 5-minute gap between administering Optive UD and any other ophthalmic products.

---

Procedural Steps for Use

Adherence to the following sequence is required for the unit-dose presentation:

1. Preparation: Wash hands before using the product. Ensure the unit dose vial is intact, and open it by completely twisting off the tab.
2. Application: Place the designated amount of drops in the affected eye(s) as needed.
3. Contamination Avoidance: Do not allow the tip of the vial to touch the eye or any other surface. This step is necessary to avoid contamination and potential eye injury.
4. Disposal: The unit-dose container is for single use only. Discard the vial immediately after use, even if solution remains inside.

Special Handling and Populations

• Vial Storage: Unused vials must be kept in the original carton or pouch. Do not use the solution if it changes color or becomes cloudy.
• Post-operative Use: If the product is used following surgery, such as LASIK, patients are directed to follow their eye doctor's specific instructions regarding post-operative care.
• Age Groups: Safety and effectiveness have not been demonstrated in pediatric patients, nor are there specific study data for use during pregnancy and lactation.

This instruction set establishes a standardized, single-use administration protocol designed to guide correct application and hygiene with the preservative-free eye drop solution.

Recent Clinical Evidence

Overview of Clinical Research

Research has been conducted investigating Optive UD in studies related to the relief of symptoms associated with dry eye disease. The clinical development program featured Phase 1, Phase 2, and Phase 3 trials involving adult participants globally. The evidence base primarily consists of randomized, controlled trials.

---

Key Study Observations

Short-Term Measures (12-Weeks)

A 12-week Phase 3 trial examined the measurement of patient comfort and quality of life as primary endpoints. This study used established standardized assessment scales for dry eye symptoms (e.g., OSDI). Participants were assessed at four and twelve weeks following the start of the intervention. Research noted metrics related to the initial observation of changes in a measured outcome compared to control.

Long-Term Follow-up

Long-term research examined participants receiving the intervention, with sustained comfort and tolerability being measured variables. A 52-week extension study collected data on continued reported measures of ocular comfort and overall quality of life using standardized collection tools.

---

Pharmacokinetics and Tolerability

Studies investigated the tear film stability profile under different conditions. Research collected data on the immediate and sustained sensation of comfort following application. Studies included participants across a range of dry eye severity levels in their analysis. Research has also included participants with concurrent use of other ophthalmic products in the study protocol.

Key Studies & References

1. Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage (Randomized Controlled Trial comparing Optive to Hylocomod)
2. Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms (Clinical Trial NCT00761202)

Common questions about Optive UD (FAQ)

Q: Is Optive UD classified as an artificial tear or a lubricant eye drop?

The official pharmacological classification for Optive UD identifies it as an Ophthalmic Protectant and Lubricating Agent.

It is also generally described in regulatory documents as a Tear Film Supplement. This classification reflects its function as a supplement designed to support the integrity of the eye's outer layer.

Q: What specific conditions or types of dry eye discomfort are the drops intended to treat?

Official product labeling indicates that Optive UD is for the temporary relief of discomfort related to eye dryness. This includes symptoms like burning and irritation.

The product is also approved for discomfort caused by exposure to environmental factors, such as wind or sun.

Q: Can Optive UD be used to re-wet contact lenses?

Yes, regulatory documents confirm that the unit dose formulation is compatible for use with all types of contact lenses. This compatibility is noted in the official eligibility profile for the product.

Q: Is it normal to feel a mild, temporary sting or burning sensation when first applying Optive UD?

Official data classifies eye irritation, including burning and discomfort, as a common adverse reaction.

This sensation is noted as typically transient, meaning it passes quickly, and often occurs immediately after the drops are instilled.

Q: Does Optive UD cause redness or irritation in the eyes?

According to official adverse reaction documents, transient eye irritation, including burning and discomfort, is listed as a common side effect. Ocular hyperemia, which is a medical term for eye redness, is listed as an uncommon adverse reaction.

Q: Does Optive UD offer protection against further eye irritation?

Yes, the official labeling for the product indicates that it may be used as a protectant. This refers to the product's function in providing a physical coating that may assist in protecting the ocular surface against further irritation.

Q: Does the product help relieve eye dryness caused by prolonged screen time or computer use?

The product is officially indicated for the relief of eye dryness symptoms caused by exposure to environmental factors like wind or sun.

While screen time is not specifically named, this official indication is consistent with the type of dryness symptoms often associated with prolonged computer or screen use.

Q: What is the function of the inactive ingredients, such as L-carnitine and Erythritol?

While classified as inactive, these components are known as osmoprotectants. Osmoprotectants help the eye's surface cells by restoring their natural osmotic balance.

This is a mechanism that supports moisture retention and helps protect the cells from stress caused by an overly salty tear film.

Q: Is there research evidence that Optive UD helps stabilize the natural tear film?

Studies and official information on the product's dual-action mechanism describe it as contributing to the mechanical integrity of the eye's outer layer.

By providing a physical barrier and modulating viscosity, this mechanism functionally supports the stability of the tear film.

Q: Can Optive UD be used to help flush irritants or debris from the eye?

The product is officially classified as an eye lubricant and protectant. The physical coating provided by the lubricating agent creates a mechanical barrier, which can assist the eye in clearing its surface.

Q: Can children use Optive UD for dry eye symptoms?

Official product documentation states that the safety and effectiveness of Optive UD have not been formally established in the pediatric population.

This is due to insufficient clinical data specifically collected for children and adolescents.

Q: Is there a maximum number of drops per eye per day that is generally considered safe?

The official administration instructions state that the drops should be used '1 or 2 drops' 'as needed.'

Regulatory documents primarily state that the dosage is based on individual need, which is consistent with its Over-The-Counter status.

Q: Does Optive UD help with watery or itchy eyes?

The product’s primary function is to relieve dryness and related discomfort. However, official safety documentation lists eye pruritus (itching) as a common adverse reaction and increased lacrimation (watering) as an uncommon adverse reaction.

Storage Requirements

Optive UD must be stored at controlled room temperature, specifically between 59° to 77°F (15° to 25°C). For product stability, the individual single-use containers must be kept within their pouch and the original carton until the time of use. The solution should be used only if it is clear and the container is intact. Like all medicines, this product must be kept out of the sight and reach of children.

---

Disposal Instructions

The single-use container is not intended to be reused and must be discarded immediately after the contents are instilled. Any unused or expired product must be disposed of in accordance with local regulatory requirements. For disposal in household trash, unused medicines can be mixed with an undesirable substance (such as dirt) and placed into a sealed container.